帕夫林治疗强直性脊柱炎临床疗效观察

目的：评价帕夫林对强直性脊柱炎的疗效和安全性。方法：分为两组。治疗组30例，常规治疗＋帕夫林胶囊，每次2粒，每日3次，口服3个月。对照组30例，常规治疗＋安慰剂，每次2粒，每日3次，口服3个月。观察临床指标，安全评价，疗效评价。结果：治疗前后两组在外周关节痛、指地距离、BASFI 3项指标有显著性差异；治疗前后实验结果显示帕夫林对肝、肾功能及血象均无明显影响；治疗前后两组疗效比较，治疗组总有效率较对照组高，但两组间无显著性差异。两组不良反应都以消化系统灰主。治疗组不良反应发生率为16．7％，对照组不良反应发生率为13．3％，两组间无显著性差异。结论：帕夫林具有抗炎、镇痛、双向免疫调节作用。副作用少而轻，病人耐受性好，较安全。特别是对腱附着点炎方面的作用较其他药物似更有优点，单独用于治疗强直性脊柱炎还不能获得满意疗效，可长期作为辅助治疗与其他治疗药物联合应用于强直性脊柱炎。     

Cisplatin,Gemcitabine, and Paclitaxel as a Salvage Second-Line Therapy for Metastatic Germ-Cell Cancer

BackgroundSecond-line salvage therapy for patients with metastatic germ-cell cancer (GCC) after the first-line combination of VIP (etoposide, ifosfamide, cisplatin) therapy has not been established. This study evaluated the efficacy and tolerability of the TGP (paclitaxel, gemcitabine, cisplatin) combination chemotherapy as a second-line salvage therapy.Patients and MethodsThe medical records of 16 consecutive patients with metastatic GCC who had been treated with first-line VIP therapy followed by second-line TGP therapy between 2005 and 2019 were reviewed and statistically analyzed. Ten patients, excluding the 6 patients treated with TGP without unequivocal progression, were included in the efficacy analysis. All 16 patients were included in the safety analysis.ResultsThe median follow-up period from initial TGP administration was 78 months (interquartile range, 46-120 months). The estimated 5-year progression-free and overall survival rates for the 10 patients in the efficacy analysis were 70% and 100%, respectively. Grade 3/4 hematologic toxicity occurred in all 16 patients, but none developed uncontrollable infections or life-threatening bleeding. One patient died of treatment-related secondary leukemia, however.ConclusionThe present study is to our knowledge the first to examine the therapeutic outcomes and safety profile of second-line TGP chemotherapy. VIP followed by TGP might be an alternative first- and second-line conventional regimen for patients with metastatic GCC in this granulocyte colony-stimulating factor era, especially for patients at a high risk of bleomycin-induced pulmonary toxicity.     

赤芍总苷对肺癌大鼠肺组织的作用机制

目的:研究赤芍总苷对肺癌大鼠肺组织的作用机制.方法:将大鼠分为正常组、模型组和赤芍总苷组,观察3组大鼠体质量的变化情况,比较3组大鼠肺指数和肺组织形态变化,及大鼠肺组织中存活素(Survivin)、鼠类肉瘤病毒癌基因(KRAS)表达及mRNA的表达.结果:在同一时间点,3组大鼠的体质量比较差异无统计学意义(P<0.05...     

Studies on thymocyte subpopulations in guinea pigs. VII. Characterization of cell populations responsive to guinea pig interleukin 1 and interleukin 2

The properties of thymocytes responding by proliferation to a mitogenic lectin (PHA), interleukin 1 (IL 1), or interleukin 2 (IL 2) were studied and compared to the properties of cells known to respond to a separate thymocyte growth factor (TGP), which has so far only been studied in guinea pigs. Thymocytes from guinea pigs were separated into subpopulations by density gradient centrifugation with Percoll and by rosette formation with rabbit erythrocytes. PHA-responsive cells were recovered exclusively in a non-rosetting, low-density population designated Ia, RFC-, constituting approximately 4 per cent of all thymocytes. Thus, according to the prevailing view of lymphocyte mitogenesis, IL 1-producing, IL 2-producing as well as IL 2-responding cells are all present in this population. The mitogen-responsive cells could be further stimulated by addition of IL 1 or IL 2, indicating that the magnitude of the mitogenic response was regulated by the production of these factors and was not restricted by the number of IL 2-responding cells. IL 1, to some extent, also enhanced the mitogen response in a non-rosetting, intermediate density population designated Ib, RFC-. None of the factors could affect the lack of mitogen responsiveness in the high-density population II, constituting approximately 85% of the total population and probably including most small cortical thymocytes. We conclude that IL 2-responding thymocytes are present above all in the quantitatively small population Ia, RFC- (shown to contain also the mature, mitogen-responding cells) and to a smaller extent in Ib, RFC- (where a deficit in IL 1-producing cells may explain the poor mitogen responsiveness), but not in the major, high-density population II. From our data, it is also evident that the mitogen, IL 1- and IL 2-reactive cells can be separated from a population of intensely proliferating thymic precursor cells which are stimulated to grow by TGP. Therefore, the growth of these immature cells does not seem to be regulated by IL 1 or IL 2 in the guinea pig.     

白芍总苷对糜烂型口腔扁平苔藓患者外周血中IFN-γ及IL-10表达的影响研究

目的:探讨白芍总苷对糜烂型口腔扁平苔藓患者外周血中IFN-γ及IL-10表达的影响。方法:选取于2014年2月~2015年3月我院皮肤科与口腔科收治的38例糜烂型口腔扁平苔藓患者为研究对象,随机分为对照组和研究组两组。对照组患者,18例,对照组患者,在清除患者口腔中残根、残冠以及牙石等,用0.1%的他克莫司软膏进行局部治疗,2次/d。研究组患者,20例,在对照组治疗的基础上采用口服白芍总苷胶囊进行治疗,比较两组患者一个疗程后的临床疗效,并采用ELISA法检测并比较治疗前后两组患者外周血中IFN-γ及IL-10的表达情况。结果:对照组,18例,其中有效者2例,好转者6例,无效者10例,总有效率为44.4%。研究组,20例,其中其中有效者8例,好转者7例,无效者5例,总有效率为75%。与对照组相比,研究组患者的总有效率显著升高,差异显著(P＜0.05)。治疗后研究组患者外周血中IFN-γ及IL-10的表达水平均显著升高,差异显著(P＜0.05),具有统计学意义。结论:白芍总苷治疗糜烂型口腔扁平苔藓具有较好的临床疗效,值得临床推广应用。同时,白芍总苷较好的临床疗效可能与其增高了患者外周血中IFN-γ水平及IL-10水平有关。     

白芍总苷治疗幼年特发性关节炎疗效观察

目的研究白芍总苷(TGP帕夫林)治疗幼年特发性关节炎(JIA)的疗效及不良反应.方法采用分组对照研究,治疗组42例应用白芍总苷早期联合应用激素、非甾体抗炎药(NSAIDs),后期以TGP为主,对照组26采用甲氨喋呤(MTX),治疗6个月,观察关节晨僵时间、疼痛指数、血沉(ESR)、C-反应蛋白(CRP)等指标,分析两组疗效;并总结二者的不良反应.结果治疗组在关节晨僵、疼痛指数、ESR、CRP和总有效率等与对照组无显著性差异P＞0.05;但治疗组激素平均用量比对照组少,激素疗程明显缩短P＜0.05;肝功能损害等严重不良反应少.结论白芍总苷对幼年特发性关节炎有效,疗效与甲氨喋呤相当,可以减少激素的用量,缩短激素的疗程,不良反应少.     

白芍总苷治疗小儿过敏性紫癜的临床有效性和安全性评价

目的观察白芍总苷胶囊（TGP）治疗小儿过敏性紫癜（HSP）的临床疗效及安全性评价。方法2012年在本院选择诊断明确的过敏性紫癜患儿40例,随机分为治疗组和对照组,对照组按常规治疗,治疗组在常规治疗的基础上加用TGP,观察2组的临床疗效、预后及复发情况。结果治疗组患儿的总有效率（95．0％）与对照组有效率（90．0％）无显著性差异,但其治愈率（85．0％）明显高于对照组的55％（P〈0．05）,3个月内的复发率明显低于对照组,临床症状：皮疹消退、关节痛缓解及腹痛缓解的时间均明显低于对照组。在不良反应发生方面：治疗组仅出现轻度的腹泻,且发生率较低,而对照组患儿部分出现了肝功能的异常。结论白芍总苷能较好地缓解HSP患儿的症状,缩短患儿症状改善的时间,且不良反应发生率低,患儿耐受性好。     

白芍总苷通过白细胞介素 -6/信号转导及转录激活蛋白 3信号通路对脂多糖诱导的急性肺炎小鼠炎症反应的影响

目的探讨白芍总苷( TGP)通过白细胞介素 -6/信号转导及转录激活蛋白 3(IL-6/STAT3)信号通路对脂多糖诱导的急性肺炎小鼠炎症反应的影响。方法本研究起止时间为 2019年 10月至 2020年 2月。选择 SPF级雄性小鼠 50只,采用随机数字表法将小鼠随机分为五组,对照组、急性肺炎模型组、 TGP低剂量组、 TGP中剂量组和 TGP高剂量组。采用苏木精 -伊红( HE)染色观察各组小鼠肺组织病理形态学;采用酶联免疫吸附测定( ELISA)检测各组小鼠肺组织肿瘤坏死因子 -α(TNF-α)、白细胞介素( IL)-1β含量;采用蛋白质印迹( Western blotting)检测各组小鼠肺组织 IL-6、STAT3、磷酸化信号转导及转录激活蛋白 3(p-STAT3)的蛋白表达水平;采用实时荧光定量 PCR(qRT-PCR)检测各组小鼠肺组织 IL-6、STAT3 mRNA表达水平。结果模型组小鼠肺组织结构被破坏,肺泡间隔增厚,大量炎性细胞浸润; TGP药物组病理改变较模型组均存在不同程度改善,白芍总苷高剂量组肺组织仅存在少量炎性细胞浸润。与对照组( 45.12±9.73)ng/L、(21.38±2.13)ng/L相比,模型组及 TGP各剂量组小鼠肺组织 TNF-α(89.30±9.26)ng/L,(84.32±5.08)ng/L,(75.36±4.67)ng/L,(64.06±5.90)ng/L、IL-1β含量( 59.69±3.60)ng/L,(56.87±     

白芍饮片趁鲜切制产业化生产工艺研究

目的:优选白芍饮片趁鲜切制产业化生产工艺客观技术参数.方法:以芍药苷、芍药总苷为质量评价指标,结合白芍饮片外观性状,系统考察白芍饮片最佳切片程度和厚度、干燥温度、干燥时间与干燥方式等,并通过中试生产,建立白芍饮片的产业化生产工艺客观技术参数.结果:初步建立鲜白芍和白芍煮后趁鲜切制产业化生产工艺,即取鲜白芍或煮制后白芍,分档,投入滚筒脱皮机内刮去外皮后,置低温烘干机60℃烘9h至近干时(白芍药材在其含水量为28％～ 32％时),取出,以适量水喷淋后,闷润2～3h,切1.5～2 mm薄片,再60℃低温烘干,放凉,密封包装.结论:白芍饮片趁鲜切制产业化生产工艺稳定,有效避免了硫黄熏制和浸润软化,产品质量较好.